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AbstrACt
Introduction Why some people develop chronic pain 
following an acute episode of low back pain is unknown. 
Recent cross- sectional studies have suggested a 
relationship between aberrant sensorimotor cortex activity 
and pain persistence. The UPWaRD (Understanding 
persistent Pain Where it ResiDes) cohort study is the first 
prospective, longitudinal investigation of sensorimotor 
cortex activity in low back pain. This paper describes the 
development of a causal model and statistical analysis 
plan for investigating the causal effect of sensorimotor 
cortex activity on the development of chronic low back 
pain.
Methods and analysis Sensorimotor cortex activity 
was assessed within 6 weeks of low back pain onset 
using somatosensory evoked potentials and transcranial 
magnetic stimulation mapping techniques. Chronic 
low back pain is defined as ongoing pain (Numerical 
Rating score ≥1) or disability (Roland Morris Disability 
Questionnaire score ≥3) at 6 months follow- up. Variables 
that could confound the relationship between sensorimotor 
cortex activity and chronic low back pain were identified 
using a directed acyclic graph and content expertise 
was used to specify known causal paths. The statistical 
model was developed ‘a priori’ to control for confounding 
variables identified in the directed acyclic graph, allowing 
an unbiased estimate of the causal effect of sensorimotor 
activity in acute low back pain on the development of 
chronic pain. The statistical analysis plan was finalised prior 
to follow- up of all participants and initiation of analysis.
Ethics and dissemination Ethical approval has been 
obtained from Western Sydney University Human Research 
Ethics Committee (H10465) and from Neuroscience 
Research Australia (SSA: 16/002). Dissemination will 
occur through presentations at national and international 
conferences and publications in international peer- 
reviewed journals.
trial registration number ACTRN12619000002189 
(retrospectively registered)
bACkground
Low back pain (LBP) is the most common 
form of persistent musculoskeletal pain and a 
leading cause of disability.1 In 2012, the direct 
healthcare costs of LBP in Australia were 
estimated at $4.8 billion,2 while in the USA, 
this figure approaches $50 billion.3 Most of 
these costs are associated with chronic LBP, 
that is, pain that has persisted for more than 
3 months. It is not understood why up to 40% 
of people with acute LBP develop chronic 
LBP.4 Interventions to prevent the develop-
ment of chronic LBP have not been effec-
tive.5 Identifying the causal mechanisms that 
explain why some people develop chronic 
LBP may guide the development of targeted 
treatment and is considered a research 
priority.6 7
Causes of a health condition are defined 
as characteristics or events necessary for the 
condition to occur,8 that is, ‘had the exposure 
differed, the outcome would have differed’.9 
Aberrant sensorimotor cortex activity in 
the acute stage of LBP is one characteristic 
strengths and limitations of this study
 ► The causal objective for data obtained from the 
UPWaRD (Understanding persistent Pain Where 
it ResiDes) study is made explicit and transparent 
within this protocol and analysis plan.
 ► Acknowledging the causal goal of this research can 
inform scientific discussion of future results.
 ► Detailed description of confounder selection using 
a directed acyclic graph is transparently reported 
‘a- priori’.
 ► A causal analysis in observational data can be 
viewed as an attempt to emulate a hypothetical trial 
— ‘the target trial’. Currently, it remains challenging 
to sufficiently define sensorimotor cortex activity as 
an ‘intervention’.
 ► There can be no guarantee that a causal model in-
corporates all confounders.
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postulated to have a causal relationship with the devel-
opment of chronic pain.10–12 Cross- sectional studies have 
shown larger activity and a shift in the S1 representa-
tion of the back11 and enlarged, overlapped and shifted 
M1 representations of the back muscles in chronic LBP 
compared with pain- free individuals,13 14 and these 
changes are associated with pain, functional impair-
ment and symptom chronicity.14–18 Further, preliminary 
evidence suggests sensorimotor cortex activity in acute 
LBP is lower in patients with acute clinical LBP than in 
pain- free controls.10 Despite these findings, no study has 
investigated the causal relationship between sensorim-
otor cortex activity in acute LBP and the development of 
chronic pain.
Recent conceptual advances have outlined methods 
for estimating the causal effect of an exposure on a 
health outcome using observational data.19 Two major 
considerations when attempting to estimate causal 
effect include how a particular target trial is emulated 
with observational data and the appropriate selection of 
confounding variables.20 21 Identification and inclusion 
of confounding variables in a statistical model is essential 
to estimate causal effects.21 Confounding occurs when an 
exposure and outcome share a common cause.22–24 Data 
driven identification of confounding variables such as p 
value based and model- based variable selection methods 
ignore the causal structure underlying the hypothesis and 
subsequently do not aid in causal inference.15 18 Rather, 
expert knowledge is required to specify the causal struc-
ture.25 Causal models can be represented visually using 
directed acyclic graphs (DAGs).9 19 26–29 A DAG provides 
a graphical representation of a mathematically rigorous 
method for minimising confounding bias within obser-
vational research.8 9 While there can be no certainty a 
causal model incorporates all known confounders, this 
approach to identifying confounding bias and developing 
a causal model makes assumptions explicit and trans-
parent, promoting informed scientific discussion.20
Using data from the UPWaRD (Understanding 
persistent Pain Where it ResiDes) prospective, longitu-
dinal cohort study, this paper reports the development 
of a causal model to investigate whether sensorimotor 
cortex activity (exposure) in the acute stage of LBP 
has a causal effect on the development of chronic LBP 
(outcome). First we describe the protocol for data collec-
tion and development of a DAG, detailing the explicit 
assumptions for identification of confounding variables 
within a causal model of chronic LBP.19 Second, we report 
a prespecified statistical analysis plan in line with the 
STROBE (Strengthening the Reporting of Observational 
Studies in Epidemiology) statement.30
MEthods
design
The UPWaRD study is a multicentre, prospective, longi-
tudinal, cohort study of people presenting with acute 
LBP (National Health and Medical Research Council of 
Australia, Grant ID: 1059116). The study was registered 
with the Australian and New Zealand Clinical Trials 
Registry and the full study protocol has been published.31 
The study enrolled 120 participants with acute LBP, with 
each participant undergoing a battery of neurophysio-
logical and psychological tests at baseline with follow- up 
completed at 6 months.
Patient and public involvement
Patients and the public were not involved in the design 
of this protocol and statistical analysis plan. Patient advo-
cacy groups (Chronic Pain Australia, Pain Australia) 
provided support for recruitment through dissemination 
of recruitment flyers in newsletters, websites and social 
media. Individual test results will be provided to partici-
pants on request and a summary of the overall outcomes 
of the study will be available to all participants on comple-
tion of the trial.
objective
The primary aim of the UPWaRD study was to determine 
whether sensorimotor cortex activity, an individual’s 
capacity for neuroplasticity, and psychosocial features, 
assessed during an acute episode of LBP could predict 
6 month LBP outcome.31 As predictive models have 
different aims to studies investigating causal inference, 
this paper outlines the statistical analysis plan for using 
data obtained from the UPWaRD study to investigate 
whether sensorimotor cortex activity has a causal effect in 
the development of chronic LBP.
hypothesis
Null hypothesis: Sensorimotor cortex activity in the 
acute stage of LBP (T1) does not cause chronic LBP at 
6 months. The null hypothesis will be rejected if sensorim-
otor cortex activity demonstrates a significant causal rela-
tionship with chronic LBP (pain or disability) at 6 month 
follow- up (T2).
Inclusion criteria
Participants were eligible for inclusion in the study if the 
following criteria were met:
 ► 18 years or older and experiencing acute non- specific 
LBP — defined as pain in the region of the lower back, 
superiorly bound by the thoracolumbar junction and 
inferiorly by the gluteal fold24;
 ► Experiencing a new episode of acute LBP defined 
as pain present for more than 24 hours and less 
than 6 weeks’ duration following a period of at least 
1 month pain- free24–26;
 ► Did not have known or suspected serious spinal 
pathology (for example, fracture, malignancy, inflam-
matory or infective diseases of the spine; cauda equina 
syndrome or neurological disorder);
 ► Did not have a history of previous lumbar spinal surgery 
(eg, spinal fusion, intervertebral disc replacement);
 ► Did not report suspected or confirmed pregnancy 
and/or were less than 6 months’ post- partum;
by copyright.
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Figure 1 Directed acyclic graph to identify confounders. Confounding variables (theoretical causal effect on exposure 
(sensorimotor cortex activity) and outcome (chronic LBP)) are in red circles. Grey circles are variables that were unmeasured in 
the UPWaRD (Understanding persistent Pain Where it ResiDes) study. LBP,low back pain.
 ► Did not present with suspected radicular pain (domi-
nant leg pain, positive neural tissue provocation tests 
and/or any two of altered strength, reflexes or sensa-
tion for the same nerve root, assessed clinically);
 ► Were free from the presence of another painful 
condition (eg, fibromyalgia, neuropathy, rheumatoid 
arthritis);
 ► Did not report serious comorbidities affecting senso-
rimotor function or causing neurological deficit (eg, 
multiple sclerosis, spinal cord injury);
 ► Did not report a history of psychological disorders 
requiring medication for symptom control (eg, major 
depressive disorder, bipolar disorder, schizophrenia);
 ► Demonstrated no contraindications for the applica-
tion of transcranial magnetic stimulation27;
 ► Provided written informed consent to participate and 
were able to speak and read English.
outcome variables: pain and disability
Primary outcome
The primary outcome is pain intensity. Self- reported 
pain scores are determined using the Brief Pain Inven-
tory at T1 and T2.32 Participants are asked to score their 
pain intensity on average over the previous week using 
an 11- point numerical rating scale (NRS: 0=‘no pain’, 
10=’worst pain imaginable’). Pain intensity scores at T2 
will also be dichotomised to determine ‘recovered’ and 
‘non- recovered’ participants. A NRS score of 0 will be 
classified as recovered LBP and a NRS score ≥1 will be 
classified as chronic LBP.33
secondary outcome
The secondary outcome is disability. Self- reported 
disability will be determined using the 24- point Roland 
Morris Disability Questionnaire (RMDQ) at T1 and T2.34 
This questionnaire detects the level of disability experi-
enced as a result of LBP. Disability scores at T2 will be 
dichotomised with a RMDQ score ≤2 classified as recov-
ered LBP and a RMDQ score ≥3 classified as chronic 
LBP.33
Exposure variables: sensorimotor cortex activity
Sensory cortex activity in the acute stage of LBP will be 
assessed using the peak- to- peak area of the N80 and N150 
components of the sensory evoked potential (SEP). 
Motor cortex activity will be assessed using transcranial 
magnetic stimulation (TMS) derived map volume of the 
paraspinal muscles at the L3 and L5 spinal level. These 
procedures have been outlined in detail in the UPWaRD 
study protocol.31 In brief:
SEPs are recorded in response to two blocks of 500 non- 
noxious electrical stimuli applied via a constant current 
stimulator (Digitimer, DS7AH) to the paraspinal muscles 
3 cm lateral to the L3 spinous process, ipsilateral to the 
side of worst LBP. Electroencephalography (EEG) is 
recorded using gold plated cup electrodes (Digitimer, 
Reusable Au and Ag EEG Cup Electrodes) positioned 
over S1 (3 cm lateral and 2 cm posterior to Cz) on the side 
contralateral to worst LBP and referenced to Fz according 
to the International 10/20 EEG placement system.35 The 
N80 component is thought to represent activity in S1 
(between the first major downward deflection of the curve 
after stimulation and the first major negative peak, N80), 
the N150 component is thought to represent activity in the 
secondary sensory cortex (S2) (between the first negative 
peak, N80, and second negative peak, N150).
10 11 15 36 37
L3 and L5 map volume is the measure of total 
excitability of the corticomotor representation 
of the paraspinal muscles recorded at L3 and L5 
level.38 39 Participants undergo a standardised TMS 
by copyright.
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Table 1 Confounding variables identified from the directed acyclic graph
Assessment domain Confounding variable
Predisposing factors 1. Age
2. Sex
3. Previous history of low back pain: Participants are asked the following question: ‘Have you 
experienced low back pain in the past?’
4. BDNF genotype: Cheek swabs taken on the day of baseline testing are used to prepare genomic 
DNA (Isohelix DNA Isolation Kit).
5. Socioeconomic status: Participant postal code is converted into a SEIFA score.52
6. Cultural diversity: Participants are asked the following question: ‘How do you define your identity, 
in ethnic or cultural terms?’
Blood biomarkers 7. BDNF serum concentration: Peripheral venous blood is drawn into serum tubes (BD Vacutainer, 
SST II Advance). BDNF serum concentration is measured using an enzyme- linked immunosorbent 
assay (ELISA) (Simple Plex Cartridge Kit, Biotrend).
8. Pro- inflammatory cytokines: Serum samples obtained from the UPWaRD study will also be 
analysed for TNF, IL-1β, IL-6 and CRP. Zero is allocated for values below the test sensitivity.53
Psychological variables 9. PCS: Assesses catastrophising thoughts about pain. The PCS includes 13 items, scored on a 
5- point scale.
10. DASS-21: Includes three 7- item subscales with higher scores indicating greater depression, 
anxiety and/or stress.
11. PSEQ: Evaluates the confidence of an individual in their ability to perform a range of functional 
activities while in pain. A total score between 0 and 60 is calculated, higher scores indicate 
greater self- efficacy beliefs.
Sensitisation 12. Local sensitivity: PPT is measured using a hand- held pressure algometer (Somedic, Hörby, 
Sweden). The probe (size 1 cm2) is applied perpendicular to the skin until the participant reports 
the sensation has changed from pressure to pain. PPT is measured three times ipsilateral to the 
side of the worst LBP, 3 cm lateral to the L3 spinous process, with the average used for analysis.
13. Distal sensitivity: PPT is measured as above on the thumb nail of the hand ipsilateral to the side of 
the worst LBP.
BDNF, brain derived neurotrophic factor; CRP, C- reactive protein; DASS-21, Depression, Anxiety and Stress Scale; IL-1β, interleukin-1β; IL-6, 
interleukin-6; LBP, low back pain; PCS, Pain Catastrophising Scale; PPT, pressure pain threshold; PSEQ, Pain Self- Efficacy Questionnaire; 
SEIFA, Socio- economic index for area; TNF, tumour necrosis factor; UPWaRD, Understanding persistent Pain Where it ResiDes.
mapping procedure.10 40 Single- pulse, monophasic TMS 
is delivered to the M1 contralateral to the side of worst 
LBP (Magstim 200 stimulator/7 cm figure- of- eight coil; 
Magstim Co Ltd, Dyfed, UK). The stimulator intensity is 
set to 100%, with an interstimulus interval of ~5 s. Surface 
electromyography (EMG) is recorded from the paraspinal 
muscles with an electrode (silver- silver chloride dispos-
able electrodes; Noraxon USA Inc, Arizona, USA) placed 
longitudinally, 3 cm lateral to the L3 spinous process and 
1 cm lateral to the L5 spinous process, ipsilateral to the side 
of worst LBP. Five stimuli are delivered over pre- marked 
scalp sites on a 6×7 cm grid, commencing at the vertex, 
determined using the International 10/20 System.13 41 
EMG traces of the five motor evoked potentials recorded 
at each scalp site are averaged then superimposed over 
the respective scalp sites to construct a topographical 
representation of the paraspinal muscle.18 All TMS data is 
analysed using MATLAB 7 (The MathWorks, USA).
Identifying sources of confounding
A directed acyclic graph was constructed using DAGitty 
software42 to identify all variables that have a plausible, 
causal effect on the relationship between sensorimotor 
cortex activity (the exposure) and chronic LBP (the 
outcome).9 Figure 1 details all variables included within 
the DAG. The DAG outlines explicit assumptions made 
by the investigators, informed by expert opinion and 
current literature.19
Table 1 details data collected from the UPWaRD 
study that can be used to control for the identified 
confounding variables. Procedures for obtaining these 
variables are outlined in detail in the UPWaRD study 
protocol.31
Limitations
The DAG methodology is not without limitation, estab-
lishing the directionalities of effects in addition to model 
misspecifications can result in errors, potentially leading 
to incorrect inferences.19 Simpler and more sparse DAGs 
represent stronger assumptions, as every omission of 
a variable and its causal pathway represents an assump-
tion of one or more causal null hypotheses.43 Further, 
DAGs do not account for the effect of unmeasured 
confounding. The effect of unmeasured confounding 
on the study results will be analysed using a sensitivity 
analysis. A sensitivity analysis determines how important 
unmeasured confounding would need to be to alter study 
conclusions.44
by copyright.
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sample size
G*Power (V.3.0.10, University of Kiel, Germany) was used 
to calculate the required sample size for estimating the 
causal effect of baseline sensorimotor activity on chronic 
LBP.45 The minimum sufficient adjustment set identi-
fied 16 confounding variables that will be controlled 
for in the causal model. According to the sample size 
calculation, 111 participants are required to detect an 
effect size of 0.2 with 80% power, using an alpha level of 
0.05, with 16 confounding variables. This calculation is 
based on detecting a medium effect for a multiple linear 
regression.46
Missing data
Completeness of data obtained from the UPWaRD study 
at T1 and T2 will be reported as recommended by the 
STROBE statement.30 Cases with missing values will be 
removed from the data set if follow- up rates are higher 
than 95% at T2. If missing data exceeds 5%, multiple 
imputation will be performed.47 The methods used for 
combining all reported estimates following multiple 
imputation will be reported (ie, Rubin’s rule).47 48 Where 
data are missing at random (ie, missing randomly, condi-
tional on covariates), estimates based on multiple impu-
tation are unbiased.49
Evaluation of demographics and baseline characteristics
Data analysis will be performed in R (The R Founda-
tion for Statistical Computing, a statistical software).50 
Continuous variables will be presented through centrality 
measures (mean, median), and dispersion (SD and IQR) 
according to the distribution, and categorical variables 
through frequencies and percentages.
statistical analyses
The primary outcome, pain intensity, will be entered into 
a linear regression model as the continuous dependent 
variable. Separate multivariable linear regression models 
for the exposure variables (N80, SEP component, N150 SEP 
component, L3 map volume and L5 map volume) will 
be developed. Confounding variables identified by the 
DAG will be adjusted for in each linear regression model. 
Linearity assumptions and model fit will be assessed.47 51 
The regression coefficient and corresponding 95% CIs 
will be reported and presented in tabular form as recom-
mended by item number 16a of the STROBE statement.30 
The probability threshold for statistical significance will 
be set at p<0.05.
To further explore a possible causal effect of sensorim-
otor cortex activity during acute LBP on the development 
of chronic LBP, pain intensity scores at 6 month follow- up 
will be dichotomised into chronic LBP (NRS score, ≥1) 
or recovered LBP (NRS score, 0). Separate logistic regres-
sion models will be created to investigate the causal effect 
of sensorimotor cortex activity measures and chronic 
LBP. Adjusted and unadjusted ORs with corresponding 
CIs will be reported once confounders identified by the 
DAG are entered into the model. To explore the effect 
of unmeasured confounding a sensitivity analysis will be 
performed and reported.44
The analysis plan will then be repeated to model the 
causal effect of sensorimotor cortex activity and the 
secondary outcome, disability. Any deviations from this 
protocol will be noted in the final manuscript.
dIsCussIon
This protocol details an ‘a- priori’ reported protocol and 
statistical plan for investigating causal inference using 
data derived from the UPWaRD prospective cohort study. 
A directed acyclic graph is presented for the selection 
of confounding variables, ensuring analytical transpar-
ency. Confounding variables entered into a multivariable 
regression analysis will determine whether sensorimotor 
cortex activity in the acute stage of LBP has a causal rela-
tionship with the development of chronic LBP.
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